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Abstract
Herbal interactions with nifedipine/felodipine through cytochrome P450 (CYP) 3A inhibition is signiﬁcant in humans.
Shengmai-San (SMS), a three-herbal formula of Chinese medicine, is commonly prescribed in Asia populations for
cardiovascular disorders. This study aimed to elucidate the impact of SMS on nifedipine/felodipine treatment by the
ﬁndings from rat pharmacokinetic study of nifedipine to the retrospective cohort study of patients with hypertension.
The 3-week SMS treatment increased the systemic exposure to nifedipine by nearly two-fold and decreased nifedipine
clearance by 39% in rats. Among the ingredients of SMS component herbs, schisandrin B, schisantherin A, and methylophiopogonanone A, inhibited the nifedipine oxidation (NFO) activities of rat hepatic and intestinal microsomes, as
well as human CYP3A4. Methylophiopogonanone A was identiﬁed as a time-dependent inhibitor of CYP3A4. After 1:5
propensity score matching, 4,894 patients with nifedipine/felodipine use were analyzed. In patients receiving nifedipine/
felodipine, the subgroup with concurrent SMS treatment had a higher incidence of headache (92.70 per 1,000 personyears) than the subgroup without SMS treatment (51.10 per 1,000 person-years). There was a positive association between
headache incidence and cumulative doses of SMS (1e60 g SMS: hazard ratio (HR): 1.39; 95% conﬁdence interval (CI):
1.11e1.74; >60 g SMS: HR: 1.97; 95% CI: 1.62e2.39; p < 0.0001). However, patients who had higher cumulative SMS doses
had a lower risk of all-cause mortality (1e60 g SMS: HR: 0.67; 95% CI: 0.47e0.94; >60 g SMS: HR: 0.54; 95% CI: 0.37e0.79;
p ¼ 0.001). Results demonstrated increased rat plasma nifedipine levels after 3-week SMS treatment and increased
headache incidence should be noted in nifedipine/felodipine-treated patients with prolonged SMS administration.
Keywords: Clearance, Headache, Methylophiopogonanone A, Nifedipine, Shengmai-San

1. Introduction

T

for

he dihydropyridine calcium channel blockers,
nifedipine and felodipine, are currently used
the treatment of various cardiovascular

disorders, including hypertension and angina [1].
The absorption of nifedipine from the gastrointestinal tract is rapid and almost 100%, but its extensive
ﬁrst-pass metabolism leads to an absolute bioavailability of 40e50% in humans [2]. The
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pharmacokinetic properties of felodipine are similar
to those of nifedipine [3]. Both nifedipine and felodipine undergo oxidative metabolism, which is
primarily catalyzed by human cytochrome P450
(CYP) 3A4 and rat CYP3A1 to generate inactive
metabolites [3e5]. The oxidative metabolite of
nifedipine, dehydronifedipine can be further
metabolized through hydroxylations and glucuronidation [6]. In humans and rats, CYP3A appears
to be the most abundant hepatic and intestinal CYP
subfamily [7,8]. Intestinal elimination encompasses
36e52% of the ﬁrst-pass metabolism of nifedipine in
humans [9], and it contributes more to ﬁrst-pass
elimination in rats than hepatic metabolism [10].
The most common side effects of nifedipine/felodipine include headaches and ﬂushing [1]. Much
attention has been paid to the interactions of
nifedipine/felodipine with herbs and fruits, such as
Ginkgo biloba and grapefruit. In a study of eight
healthy participants, compared to the ingestion of
nifedipine alone, two subjects had an approximately
2-fold increase in the peak plasma concentration of
nifedipine and severer and longer-lasting headache
after concurrent ingestion of nifedipine and G.
biloba leaf extract [11]. In another study of nine
healthy participants, plasma felodipine concentrations increased (with an up to 48% increase of area
under the plasma concentration versus time curve
(AUC)) after pretreatment (1e24 h) with one glass of
grapefruit juice [12]. The number of participants
experiencing headaches increased from three to
nine when felodipine was taken 4 h after grapefruit
juice ingestion.
Grapefruit juice has been demonstrated to
decrease intestinal, but not hepatic CYP3A activity
in humans [3]. The furanocoumarin-type ingredients of grapefruit juice inhibit human intestinal CYP3A4 in a time-dependent manner, leading to
irreversible CYP3A inactivation [13]. A typical
characteristic of time-dependent CYP inhibitors is
that their inhibitory effect can be enhanced by
reduced nicotinamide adenine dinucleotide phosphate (NADPH)-fortiﬁed pre-incubation of the inhibitor with the CYP, in which the active metabolite
of the inhibitor is formed and binds the CYP tightly.
The recovery t1/2 of the grapefruit juice (2 h prior to
midazolam administration)-elevated AUC of midazolam (a 65% increase) was estimated to be 23 h,
and complete recovery required 3 days in healthy
participants [14]. Moreover, the increases in the
maximum concentration (Cmax) and AUC of plasma
felodipine after ﬁve consecutive days of grapefruit
juice ingestion were signiﬁcantly greater than those
after ingesting a single glass of grapefruit juice [3].

Abbreviations
AMI
AUC

acute myocardial infarction
area under the plasma concentration versus time
curve
CI
conﬁdence interval
CL/F
clearance/fraction absorbed
Cmax
maximum concentration
CPR
NADPH-cytochrome P450 reductase
CYP
cytochrome P450
DMSO dimethyl sulfoxide
HHF
hospitalization due to heart failure
HPLC
high performance liquid chromatography
HR
hazard ratio
IPTG
isopropyl b-D-1-thiogalactopyranoside
MS/MS tandem mass spectrometry
NADPþ nicotinamide adenine dinucleotide monosodium
phosphate
NADPH reduced nicotinamide adenine dinucleotide monosodium phosphate
NFO
nifedipine oxidation
PSM
propensity score matching
SJW
St. John's wort
SMS
Shengmai-San
StD
standardized mean difference
t1/2
half-life
TCM
traditional Chinese medicine
tmax
time to maximum plasma concentration
UPLC
ultra-performance liquid chromatography

In addition to headaches, increased heart rate and
enhanced reduction in blood pressure have been
reported in participants taking both grapefruit and
felodipine [12]. Other relatively uncommon but severe adverse effects of calcium-cand myocardial
infarction [15e17]. These reports revealed that
elevated plasma levels of nifedipine and felodipine
are highly associated with the incidence of adverse
effects. Repeated treatments can enhance the pharmacokinetic alterations induced by time-dependent
CYP3A inhibitors.
A traditional herbal formula Shengmai-San (SMS)
is prepared from Ginseng Radix (roots of Panax
ginseng), Ophiopogonis Radix (roots of Ophiopogon
japonicus), and Schisandrae Fructus (fruits of Schisandra chinensis), and has been used to treat cardiovascular diseases [18e20]. From 2000 to 2010,
sixteen percent of the prescriptions for the treatment of ischemic heart disease in traditional Chinese medical care in Taiwan contained SMS [21]. In
TCM therapy, SMS decoction can be used for up to
3 weeks in patients [22]. Similar to CYP3A inhibition
by grapefruit juice, SMS extract inhibits CYP3A
activity in a time-dependent manner [23]. The 1-h
SMS pretreatment decreased nifedipine clearance
by 34% and hepatic nifedipine oxidation (NFO) activity by 49%. However, intestinal, but not hepatic

microsomal NFO activity decreased in 3-week SMStreated rats [24]. These ﬁndings indicate the dynamic irreversible inhibition of NFO by SMS in vivo
and warrant the present studies on the effects of 2and 3-week SMS treatments on the pharmacokinetics of nifedipine in rats. Ketoconazole and St.
John's wort (SJW) were studied as the positive
controls of CYP3A inhibitor and inducer, respectively [23,25]. In addition to CYP3A inhibition, ketoconazole inhibited the glucuronidation activity
potently [26]. The inhibitory effects of the ingredients of SMS component herbs on the NFO
activities of rat hepatic and intestinal microsomes,
as well as recombinant human CYP3A4, were
determined. In addition, a single-pay mandatory
National Health Insurance (NHI) program was
implemented in 1995 in Taiwan and covered more
than 99% of the 23 million residents. The NHI in
Taiwan provides comprehensive health care,
including ambulatory visits, hospital admissions,
procedures, medications, rehabilitation, and traditional Chinese medicine (TCM). By using the data of
NHI claims, the risks and beneﬁts of health outcomes, considering the combined treatments of
nifedipine/felodipine and SMS in patients with hypertension, were evaluated.

2. Materials and methods
2.1. SMS, chemicals and solvents
The powdered decoction of SMS (Lot # 15083105;
containing 0.56 ± 0.01 mg/g schisandrol A,
0.10 ± 0.001 mg/g schisandrin A, 0.20 ± 0.003 mg/g
schisandrin B and 0.01 mg/g ophiopogonin D) [23,24]
was purchased from Sun Ten Pharmaceutical Co.,
Ltd. (New Pharmaceutical Inspection Convention
and Pharmaceutical Inspection Co-operation
Scheme (PIC/S). The content of methylophiopogonanone A was determined using liquid
chromatography (LC)-tandem mass spectrometry
(MS/MS) (multi-reaction monitoring transition:
341.1 / 178.0) following the method reported previously for the determination of ophiopogonin D [24].
There was 0.02 mg/g methylophiopogonanone A in
SMS decoction. The SMS was prepared from Schisandrae Fructus, Ginseng Radix, and Ophiopogonis
Radix (1:2:2). The herbal materials and protocols for
the preparation of SMS is under the regulation of The
Pharmaceutical Affairs Act of Taiwan and the Regulations for Registration of Medicinal Products, Ministry of Health and Welfare, Taiwan. The
identiﬁcation and quality control of dried herbs used
for the decoction preparation were carried out according to the Taiwan Herbal Pharmacopeia
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(Ministry of Health and Welfare, Taipei, Taiwan). Mr.
Chang-Ming Cheng (Non-Proﬁt Organization Brion
Research Institute of Taiwan, Taiwan) is the specialist
responsible for the materials used for decoction
preparation. One gram of SMS contained 0.52 g dried
decoction and 0.48 g corn starch. The ethanolic (60%
ethanol) extract of SJW (Hypericum perforatum) (Lot #
133975; 1.3 mg/g hyperforin) [27] was purchased from
APOMEDICA Pharmaceutical Products GmbH
(Graz, Austria). Ampicillin, glucose-6-phosphate,
isopropyl
b-D-1-thiogalactopyranoside
(IPTG),
NADPþ, and nifedipine were purchased from
SigmaeAldrich Co. (St. Louis, MO, USA). Dehydronifedipine (purity >98%) was synthesized and
generously provided by Dr. F. Peter Guengerich
(Vanderbilt University, Nashville, TN, USA) [4]. The
ingredients (PubChem), ginsenoside Rb1, ginsenoside Rd, methylophiopogonanone A, ophiopogonin
D, and schisantherin A were purchased from SunHank Technology Co., Ltd. (Tainan, Taiwan) (purity
98%). Arctigenin, panaxatriol, protopanaxatriol,
and ruscogenin were purchased from MedChemExpress LLC (Monmouth Junction, NJ, USA). Schisandrin B (purity 98%) was purchased from Cayman
Chem. (Ann Arbor, MI, USA). Acetonitrile,
dichloromethane, dimethyl sulfoxide (DMSO) and
methanol were purchased from Merck KGaA
(Darmstadt, Germany).
2.2. Expression of recombinant human CYP3A4
monooxygenase system
The CYP3A4 constructs with N-terminal modiﬁcations were generously provided by Dr. F. Peter
Guengerich (Nashville, TN, USA) [28]. Bicistronic
human constructs consisting of the CYP coding
sequence, followed by that of NADPH-dependent
CYP reductase (CPR), were transformed into
Escherichia coli DH5a by electroporation (Gene
Pulser II, Bio-Rad, Hercules, CA, USA). The bacteria
were incubated in LuriaeBertani medium containing 0.1% glucose and 100 mg/mL ampicillin. The
overnight incubation was further incubated in
Terriﬁc Broth containing 1 mM thiamine, a mixture
of trace elements, 100 mg/mL ampicillin, and 1 mM
IPTG [28]. After 24 h, membrane fractions were
prepared by differential centrifugation, and the CYP
content of the membranes was determined using
CO-difference spectral analysis [29].
2.3. Rat treatments
The study was conducted according to the
guidelines of the Declaration of Helsinki, and
approved by the Institutional Animal Care and Use
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Committee (IACUC) of the National Research
Institute of Chinese Medicine and National Defense
Medical Center (Taipei, Taiwan) for the studies on
microsomal activities (IACUC #108-635-1, 110-636-1)
and pharmacokinetics (IACUC #18e240), respectively. Male SpragueeDawley rats (5 weeks old,
weight: 90e120 g) were purchased from the Animal
Center of National Yang-Ming University (Taipei,
Taiwan) or BioLASCO Taiwan Co., Ltd. (Taipei,
Taiwan). Before experimentation, the rats were
allowed a one-week acclimation period at the animal quarters (23 ± 2  C, 12-h daylight cycle). The
human-equivalent dose of SMS (powdered decoction) in rats was estimated to be 1.2e2.0 g/kg/day,
based on a 50e60-kg person (daily dose: 12e16 g)
[23]. To assess pharmacokinetic interactions, the rats
were treated with 1.9 g powdered SMS decoction/
kg/day. The SMS and SJW were ground (using a
mortar and pestle), suspended in water, mixed by
vortexing, and then administered to the rats by
gastrogavage. The same volume of water was
administered to the control group.
2.4. Pharmacokinetic analysis
In ketoconazole group, rats were treated with
20 mg/kg ketoconazole together with nifedipine
(3 mg/kg, in 50% polyethylene glycol 400). Each
morning, the rats were orally administered 0.3 g/kg
SJW extract for 2 weeks and 1.9 g/kg powdered SMS
decoction for 2 and 3 weeks. To prevent the acute
effects of SMS from interfering with the assessment
[23], nifedipine was administered 20 h after the last
herbal treatment. The control group received the
same volume of vehicle. Blood samples (0.25 mL in
heparinized tubes) were collected from tail vein
using a catheter [23]. After blood sampling, the same
volume of 0.9% saline was infused back into the rats
for maintaining body ﬂuid volume. Plasma nifedipine and dehydronifedipine concentrations were
determined using an ultra high-performance liquid
chromatography (UPLC)-MS/MS system (Shimadzu
Nexera series LC-40B X3 (Schimadzu corporation,
Kyoto, Japan) equipped with a Biosystems-Sciex API
3000 series triple-quadrupole mass spectrometer
(SCIEX, Foster City, CA, USA)). Conditions set in
the LC and MS/MS systems for the quantitation of
nifedipine and dehydronifedipine primarily followed the method reported previously [23] with
slight modiﬁcation. In this study, an ultra highpressure
column
(Waters
Symmetry
C18,
2.1  100 mm, 1.7 mm, Waters Corporation, Milford,
MA, USA) was used and separation was performed
using 40% A (2 mM ammonium formate and 0.1%
formic acid in water) and 60% B (2 mM ammonium

formate and 0.1% formic acid in acetonitrile) at a
ﬂow rate of 0.2 mL/min. Pharmacokinetic parameters were obtained using non-compartmental model
analysis (WinNonlin version 5.3, Pharsight Corporation, Mountain View, CA, USA). The Cmax, AUC,
half-life (t1/2), and clearance (clearance/fraction
absorbed; CL/F) were estimated.
2.5. Preparation of microsomes and activity
determinations
Liver and intestinal microsomes were prepared by
differential centrifugation as described previously
[24], and the microsomal samples were stored at
75  C. Microsomal UDP-glucuronosyltransferase
activity was determined using p-nitrophenol as a
substrate [24]. The generation of dehydronifedipine
in the NFO assay was determined using high-performance liquid chromatography (HPLC) or UPLC
as described previously [24]. In the in vitro inhibition
studies, the rat microsomes were pre-incubated
with individual ingredients in the presence of an
NADPH-generating system (10 mM glucose-6phosphate, 0.5 mM NADPþ, and 0.5 U/mL glucose6-phosphate dehydrogenase) for 10 min prior to the
initiation of the NFO reaction by the addition of
nifedipine [23]. Microsomal activity was normalized
to the protein concentration determined using the
method reported by Lowry et al. [30]. The concentration causing 50% inhibition (IC50) of activity was
estimated using GraFit software (Erithacus Software
Ltd., Staines, UK). The inhibitory effects of ingredients on the NFO activity of bacterial membranes expressing human CYP3A4 were determined
in the absence and presence of 10-min pre-incubation to obtain the IC50() and IC50(þ) values,
respectively.
2.6. Kinetic analyses and threshold concentration
estimation
The inactivation rate (Kapp) was determined as the
slope calculated by linear regression analysis of the
plot of the natural logarithm of the percentage of
remaining activity versus pre-incubation time. The
kinact (maximal inactivation rate constant) and KI
(concentration required for half-maximal CYP3A4
inactivation) values were obtained from nonlinear
regression of the equation Kapp¼ (kinact,I)/(I þ KI),
with the initial values calculated from the double
reciprocal plot of inactivation rate versus methylophiopogonanone A concentration. The irreversible
inhibition was further conﬁrmed by determining the
remaining NFO activity after dialysis (Supplementary Methods). In the drugedrug interactions, an

AUC changes  2-fold should be considered to be
noted in the clinical application [31]. The predicted
threshold of unbound inhibitor concentration
causing a 2-fold AUC change was calculated using
high-throughput methods or inactivation kinetics
(Suppl. Methods).
2.7. Data source
The data used in this study were obtained from
the Longitudinal Generation Tracking Database
2010 (LGTD 2010) maintained by the Health and
Welfare Science Center. The LGTD 2010 contained
medical claims from two million enrollees randomly
sampled from the NHI registry in 2010. The NHI
enrollees included in the LGTD do not differ
signiﬁcantly from the overall population of NHI
enrollees in terms of age, gender, insured salary and
household location. The accuracy of the diagnoses
of major diseases, including diabetes mellitus and
stroke, in the NHI claims database has been validated previously [32,33]. This study was approved
by the Joint Institutional Review Board (JIRB No.:
17-S1-017-1).
2.8. Study subjects
This was a retrospective cohort study. Adult patients who had been diagnosed with hypertension
from 2015e2017 (International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation
[ICD-9-CM]: 401e405; ICD-10-CM: I10eI15, N26.2)
on three or more ambulatory care claims or in an
inpatient setting were identiﬁed. The patients with
hypertension were followed up from the date of
initial diagnosis until the incidence of headache, low
blood pressure, hospitalization due to acute
myocardial infarction (AMI), hospitalization due to
heart failure (HHF), death, or study end (December
31, 2018).
In Taiwan, both drugs and TCMs are included in
NHI beneﬁts. Patients can choose to have an
ambulatory visit to Western medicine doctors (e.g.,
internal medicine or family medicine) and TCM
doctors in the same therapeutic period. Patients
receiving nifedipine or felodipine (monotherapy or
combination therapy) were deﬁned as the nifedipine/felodipine group (ATC codes: C08CA05,
C08GA01, CA08CA55, CA08CA02, C07FB03,
C07FB02, and C09BB05). Patients who received
nifedipine/felodipine
combined
with
SMS
(powdered decoction) prescribed by a TCM doctor
were deﬁned as the nifedipine/felodipine þ SMS
group. Patients who had been prescribed nifedipine/felodipine for less than 28 cumulative days and
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those who had taken SMS for less than 7 cumulative
days were excluded. The cumulative dose (g) of
SMS was determined by aggregating the total
amount dispensed by the prescribed dose for each
patient from the ﬁrst date that patients received
nifedipine/felodipine to the incidence of undesired
health outcome or study end (December 31, 2018).
The median cumulative dose of SMS was 60 g.
Among the included patients, SMS use was subdivided into cumulative dosages of 1e60 g and >60 g
to examine if there was a statistically signiﬁcant
trend in dose-dependence.
2.9. Adverse health outcomes and mortality
The primary outcomes of this study were the
occurrence of adverse events, including headaches,
low blood pressure, hospitalization due to AMI, and
HHF. Headaches and low blood pressure were
deﬁned as ambulatory or hospital admission for
headache or low blood pressure after taking nifedipine/felodipine. If a patient was hospitalized with
AMI or HHF as the primary diagnosis, this was
deﬁned as hospitalization due to AMI or HHF. Details of the case deﬁnitions for the primary outcomes
are listed in Table S1. The secondary endpoint of the
study was mortality, and we linked the LGTD to the
Cause of Death data using scrambled identiﬁcation
to obtain the vital status of each patient.
2.10. Statistical analyses
Patient baseline characteristics (including age and
sex), year of cohort entry (hypertension), comorbidities in the prior year, prior medications
(including antihypertensive drugs, statins, non-steroidal anti-inﬂammatory drugs, metformin, and
insulin) were collected. We employed propensity
score matching (PSM) to minimize selection bias.
We matched the nifedipine/felodipine and nifedipine/felodipine þ SMS groups on the logit of the
propensity score using a caliper width of 0.2, the
standard deviation of the logit. A matching ratio of
1:5 was used. The standardized mean difference
(StD) between the covariates of these two groups
after PSM was less than 10%, indicating good balance among the groups. The hazard ratio (HR) for
the occurrence of adverse health effects was determined using Cox proportional hazard regression
with robust variance estimation, and the trend in
dose-dependent effects ( p-value for trend) was also
examined. A negative control outcome, bone fracture due to a vehicle accident, was used to detect
and adjust for residual systematic bias [34]. All
statistical analyses were performed using SAS
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version 9.4 for Windows (SAS Institute, Cary, NC,
USA), and a two-sided p-value of <0.05 was
considered statistically signiﬁcant. Differences
among >2 data sets were analyzed by one-way
analysis of variance (ANOVA) followed by a posthoc Dunnett's test (for comparisons with the control
group). A two-tailed p value of <0.05 was considered statistically signiﬁcant.

3. Results
3.1. Effects of repeated SJW and SMS treatments on
pharmacokinetics of nifedipine and
dehydronifedipine in rats
While ketoconazole-treatment caused an 81%
decrease of nifedipine clearance, the Cmax, AUC0-t,
and AUC0-∞ of nifedipine increased by 135%, 233%,
and 550%, respectively (Table 1 and Fig. 1A). Ketoconazole prolonged the half-life of nifedipine by
4-fold. Oral administration of SJW to rats signiﬁcantly increased hepatic NFO activities by 51%
(control group: 1.28 ± 0.08 nmol/min/mg protein;
SJW group: 1.93 ± 0.15 nmol/min/mg protein)
without affecting the glucuronidation activity of
UDP-glucuronosyltransferase
(control
group:
33.0 ± 3.0 pmol/min/mg protein; SJW group:
33.9 ± 3.4 pmol/min/mg protein). SJW treatment
increased the mean clearance of plasma nifedipine
by 28% and prolonged the time to maximum
plasma concentration (tmax) by 97%. In rats treated
with SMS for 2 weeks, the change in pharmacokinetic parameters of nifedipine was not statistically
signiﬁcant (Table 1). After treatment with SMS for 3
weeks, the mean Cmax and AUC0-t values of nifedipine were elevated by 101% and 73%, respectively.

The AUC0-∞ values of nifedipine increased by 66%,
but without statistical signiﬁcance. The 3-week SMS
treatment signiﬁcantly decreased the clearance of
nifedipine by 39% without affecting its half-life.
After nifedipine administration, plasma dehydronifedipine concentrations were also determined
in rats. Ketoconazole increased the Cmax, AUC0-t,
and AUC0-∞ values of dehydronifedipine by 125%,
270%, and 191%, respectively (Table 1 and Fig. 1B).
Ketoconazole-treatment prolonged the half-life of
dehydronifedipine by 150%. Administration of SJW
to rats prolonged the tmax by 209% without affecting
the AUC and clearance of dehydronifedipine. The 2and 3-week SMS treatments did not cause any signiﬁcant changes in the pharmacokinetic parameters
of dehydronifedipine.
3.2. Inhibition of nifedipine oxidation activities of
rat microsomes and human CYP3A4 by herbal
ingredients of SMS
The inhibitory effects of SMS ingredients on rat
microsomes were determined after a 10-min
NADPH-fortiﬁed pre-incubation with each ingredient. The Schisandrae Fructus ingredients, schisantherin A and schisandrin B, inhibited hepatic
and intestinal microsomal NFO activity with IC50
values of <10 mM (Table 2). Among the ingredients
of Ginseng Radix, only panaxatriol inhibited intestinal NFO activity, and this effect was mild. Methylophiopogonanone A is an ingredient found in
Ophiopogonis Radix [35], and it inhibits both hepatic and intestinal NFO activity. By increasing their
concentrations to 100 mM, arctigenin and ruscogenin
inhibited NFO activity by no more than 50%. Thus,

Table 1. Effects of ketoconazole, SJW and SMS on the pharmacokinetic proﬁles of nifedipine and dehydronifedipine in rats.
Parameters

Control

Ketoconazole

SJWa

SMSb
2 weeks

Nifedipine
Cmax (mg/mL)
tmax (h)
AUC0-t (h∙mg/mL)
AUC0-∞ (h∙mg/mL)
t1/2 (h)
CL/F (l/h/kg)
Dehydronifedipine
Cmax (mg/mL)
tmax (h)
AUC0-t (h∙mg/mL)
AUC0-∞ (h∙mg/mL)
t1/2 (h)

1.97
0.38
3.87
4.12
1.42
0.75

±
±
±
±
±
±

0.08
0.06
0.27
0.30
0.14
0.06

4.62 ± 1.02**
0.40 ± 0.06
12.90 ± 2.40**
26.78 ± 5.80**
5.66 ± 0.42**
0.14 ± 0.03**

0.04
0.54
0.10
0.13
2.36

±
±
±
±
±

0.01
0.10
0.01
0.01
0.33

0.09
0.90
0.37
0.78
5.89

±
±
±
±
±

0.01**
0.19
0.03**
0.12**
1.01**

3 weeks

1.01
0.75
2.57
3.18
2.23
0.96

±
±
±
±
±
±

0.16
0.11**
0.20
0.17
0.48
0.05*

3.01
0.33
4.33
4.42
1.24
0.68

±
±
±
±
±
±

0.21
0.05
0.21
0.19
0.20
0.03

3.96
0.33
6.69
6.84
1.12
0.46

±
±
±
±
±
±

0.53**
0.05
0.68*
0.67
0.15
0.04**

0.02
1.67
0.07
0.12
4.22

±
±
±
±
±

0.003
0.31*
0.01
0.02
0.82

0.04
1.64
0.11
0.12
2.01

±
±
±
±
±

0.01
0.79
0.02
0.02
0.72

0.04
1.46
0.12
0.14
1.82

±
±
±
±
±

0.01
0.43
0.02
0.02
0.19

Rats (n ¼ 6 in each group) were orally treated with a0.3 g/kg/day SJW for 2 weeks or b1.9 g/kg/day SMS for 2 or 3 weeks before the
administration of nifedipine (3 mg/kg, oral). In ketoconazole group, 5 rats were orally treated with 20 mg/kg ketoconazole together with
nifedipine. Results represent the means ± SEM. *p < 0.05; **p < 0.01, compared to the control group (One-way ANOVA analysis with a
post-hoc Dunnett's test).
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Fig. 1. Effects of ketoconazole, SJW and SMS treatments on the pharmacokinetics of nifedipine (A) and dehydronifedipine (B) in rats. A single oral
dose of ketoconazole (20 mg/kg) was administered together with nifedipine (3 mg/kg, oral) to 5 rats. Rats (6 rats in each group) were orally treated
with 0.3 g/kg SJW (suspended in water) for 2 weeks or 1.9 g/kg SMS decoction (suspended in water) for 2 or 3 weeks. The control group (6 rats)
received the same volume of water. After water/ketoconazole/herbal treatments, nifedipine was orally administered to the rats as described in the
section of Methods. Data represent the means ± SEM. *p < 0.05, compared to the control group.

in the in vitro rat microsome study, schisantherin A,
schisandrin B, and methylophiopogonanone A were
identiﬁed as inhibitors of hepatic and intestinal
NFO (Table 2).
In the recombinant human CYP3A4 system,
schisantherin A, schisandrin B, and methylophiopogonanone A caused an IC50 shift after
10 min of NADPH-fortiﬁed pre-incubation (Table 3),
indicating time-dependent inhibition. Using the
IC50 values (high-throughput screening method),
the predicted threshold of unbound concentrations
of these inhibitors able to increase the AUC 2-fold
was <50 nM (Table 2). The results showed that the
rat CYP3A inhibitors identiﬁed in SMS also inhibited the NFO activity of human CYP3A4. Besides
schisandrin B and schisantherin A, methylophiopogonanone A inhibited human CYP3A4 in a
time-dependent manner.

3.3. Time-dependent inactivation of human
CYP3A4 by methylophiopogonanone A
The
methylophiopogonanone
A-mediated
decrease in NFO activity increased with prolonged
NADPH-fortiﬁed pre-incubation time (Fig. 2A).
After incubating CYP3A4 with increasing concentrations of methylophiopogonanone A for 30 min to
ensure complete inactivation, titration of the
remaining NFO activity of CYP3A4 generated a
partition ratio of 54, which represents the molar
ratio of methylophiopogonanone A metabolized per
CYP3A4 inactivated (the turnover number appeared
to be 55, Fig. 2B). With NADPH-fortiﬁed pre-incubation, nonlinear regression analysis of the timedependent inactivation generated kinact and
apparent KI values of 0.068 ± 0.009 min1 and
13.3 ± 5.9 mM (r ¼ 0.98), respectively (Fig. 2C). Linear
regression analysis of the double reciprocal plots for
inactivation rate and methylophiopogonanone A
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Table 2. Effects of ingredients of SMS component herbs on nifedipine oxidation (NFO) activities in rat hepatic and intestinal microsomes in vitro.
SMS component herbs

IC50 (decoction: mg/mL)b (ingredient: mM)

Decoctiona or ingredient

Liver
SMS
Schisandrae Fructus

Ginseng Radix

Ophiopogonis Radix

Intestine

4.0 ± 0.5
0.54 ± 0.08
3.9 ± 0.5
4.4 ± 0.5
>6.0
>100
80.2 ± 33.3
>100
>100
>15.0
>100
16.8 ± 2.6
>100
>100

2.7 ± 0.4d
0.12 ± 0.02
8.9 ± 1.4
2.1 ± 0.7
>6.0
>100
>100
46.5 ± 9.1
>100
5.2 ± 1.2
>100
11.6 ± 0.7
>100
>100

c

Decoction
Decoction
Schisandrin B
Schisantherin A
Decoction
Ginsenoside Rb1
Ginsenoside Rd
Panaxatriol
Protopanaxatriol
Decoction
Arctigenin
Methylophiopogonanone A
Ophiopogonin D
Ruscogenin

In the absence of ingredients, rat hepatic and intestinal microsomal NFO activities were 0.81e1.35 nmol/min/mg protein and
7.1e11.8 pmol/min/mg protein, respectively. The inhibition was determined in the assays with 10-min NADPH-fortiﬁed pre-incubation
of microsomes with ingredients. Results represent the curve-ﬁtting result with the estimates of variance (denoted by ±) of a set of data of
the mean percentage of remaining activities of separated determinations of 3 rats. aThe ethanolic extracts of herbal decoctions were used
in the study of inhibition in vitro. bThe extraction yield was calculated and the IC50 value was calculated as mg decoction/mL. The IC50
values for the SMS-mediated inhibition were reported in our previous studies [22]c and [23]d.

concentration generated kinact and apparent KI
values for CYP3A4 of 0.058 min1 and 9.1 mM
(r ¼ 0.97), respectively (Fig. 2D). The predicted
threshold for causing a 2-fold increase in AUC using
inhibition constants was 79.7 nM. With a 30-min
NADPH-fortiﬁed pre-incubation, the inhibition of
NFO by methylophiopogonanone A could not be
restored after dialysis. In the recombinant CYP3A4
system, CPR is the electron-transfer partner of CYP,
and its activity was not affected by methylophiopogonanone A either before or after dialysis
(Fig. 2E). These results demonstrate that methylophiopogonanone A, a component of Ophiopogonis
Radix, irreversibly suppresses the NFO activity of
human CYP3A4 through time-dependent inhibition.
3.4. Inﬂuence of increased cumulative doses of SMS
on health outcomes
Baseline characteristics of patients were described
in Supplementary materials (Suppl. Fig. 1). The

demographic data, including age, sex, year of diagnosis, comorbidities, and prior medication use, are
shown in Table 4. There was a good balance in
baseline characteristics between the nifedipine/
felodipine and nifedipine/felodipine þ SMS groups.
The incidence rate (IR) of headache was 57.10 per
1,000 person-years in the nifedipine/felodipine
group and 92.70 per 1,000 person-years in the
nifedipine/felodipine þ SMS group. Compared to
the nifedipine/felodipine group, patients in the
nifedipine/felodipine þ SMS group had a signiﬁcantly higher risk of incident headache (HR: 1.68;
95% conﬁdence interval (CI): 1.44e1.97; p < 0.0001)
(Table S2). The risks of low blood pressure, hospitalization for AMI, and HHF were similar between
the two groups. In addition, there was a signiﬁcantly
lower mortality in the nifedipine/felodipine þ SMS
group than in the nifedipine/felodipine group (HR:
0.38; 95% CI: 0.12e0.78; p ¼ 0.0002). Lastly, the effect
of concomitant use of nifedipine/felodipine and
SMS on bone fracture due to a vehicle accident was

Table 3. Inhibitory effects of the extract of SMS decoction and herbal ingredients, schisandrin B, schisantherin A, and methylophiopogonanone A, on
nifedipine oxidation (NFO) activity of human CYP3A4 in a recombinant enzyme system.
Decoction or herbal ingredient

IC50()
(mM)

IC50(þ)
(mM)

Ratio
IC50(þ)/IC50()

Predicted
threshold (nM)

SMS
Schisandrin B
Schisantherin A
Methylophiopogonanone A

>6 (mg/mL)a
6.1 ± 1.4
0.17 ± 0.05
36.5 ± 7.0

0.26 ± 0.09 (mg/mL)a
1.5 ± 0.2
0.06 ± 0.01
17.4 ± 2.1

<0.04
0.25
0.35
0.48

e
7.69
0.34
45.0

In the absence of pre-incubation and ingredients, CYP3A4 exhibited NFO activity of 4.13 ± 0.11 nmol/min/nmol cytochrome P450 in the
recombinant monooxygenase system. Ethanolic extract of SMS decoction was used in this inhibition study. aThe extraction yield was
calculated and the IC50 value was calculated as mg decoction/mL. Results shown in the second and third columns are the mean IC50
values ± estimates of variance estimated from curve-ﬁtting analysis (n ¼ 2e3). The predicted threshold of unbound inhibitor concentration causing a 2-fold AUC increase was calculated using the high-throughput method28. “e” not calculated.
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Fig. 2. Irreversible time-dependent inhibition of NFO activity by methylophiopogonanone A (MA) in a recombinant CYP3A4 system. (A) Effects of
prolonged pre-incubation on the inhibitory effect of MA (in DMSO) on nifedipine oxidation activity of human CYP3A4. (B) Plot of remaining activity
versus the molar ratio of MA to CYP3A4. (C) Plot of inactivation rate versus MA concentration. (D) Double-reciprocal plot of inactivation rate and
MA concentration. (E) CPR and NFO activities of MA-inactivated recombinant CYP3A4 system before and after dialysis. In the control assay, the
same concentration of DMSO was included. Data represent the means ± SEM (A and E) or means (BeD) of three determinations.

explored. The IRs of bone fracture due to a vehicle
accident were 3.18 and 1.17 per 1,000 person-years
in the nifedipine/felodipine and nifedipine/
felodipine þ SMS groups, respectively. Comparing
co-treatment with SMS to the use of nifedipine/
felodipine alone, there was no signiﬁcantly different
risk of experiencing fractures between the two

groups (HR: 0.38; 95% CI: 0.12e1.24; p ¼ 0.1096). The
results showed that the concurrent use of SMS in
nifedipine/felodipine-treated patients increased the
risk of headache, but improved survival.
The dose-dependent effect of the concomitant use
of SMS on health outcomes is further demonstrated
in Table 5. Compared with the non-SMS group, an
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Table 4. Baseline characteristics of the hypertensive patients included in this study.
Variable

n
Age (mean ± SD)
Sex
Male
Female
Diagnosed year
2015
2016
2017
2018
Prior used medication
Angiotensin-converting enzyme inhibitor
Angiotensin receptor blocker
Other b-blocker
Other calcium channel blocker
Thiazides
Nitrates
Other anti-hypertension drugs
Statin
Non-steroidal anti-inﬂammation drug
Metformin
Insulin
Comorbidity
Diabetes mellitus
Ischemic heart disease
Myocardial infarction
Stroke
Congestive heart failure
Atrial ﬁbrillation

Nifedipine/Felodipine group

Nifedipine/Felodipine þ SMS group

n (%)

n (%)

4,078
64.65 ± 14.18

816
64.79 ± 12.71

1,595 (39.11)
2,483 (60.89)

323 (39.58)
493 (60.42)

0.010

2,861 (70.16)
693 (16.99)
383 (9.39)
141 (3.46)

556 (68.14)
164 (20.10)
80 (9.80)
16 (1.96)

0.006

500 (12.26)
1,900 (46.59)
1,789 (43.87)
1,648 (40.41)
246 (6.03)
485 (11.89)
459 (11.26)
1,059 (25.97)
3,189 (78.20)
749 (18.37)
224 (5.49)

104 (12.75)
395 (48.41)
376 (46.08)
337 (41.30)
50 (6.13)
98 (12.01)
101 (12.38)
222 (27.21)
639 (78.31)
148 (18.14)
48 (5.88)

0.015
0.036
0.045
0.018
0.004
0.004
0.034
0.028
0.002
0.006
0.015

1,099 (26.95)
787 (19.30)
10 (0.25)
271 (6.65)
256 (6.28)
87 (2.13)

225 (27.57)
164 (20.10)
2 (0.25)
57 (6.99)
53 (6.50)
16 (1.96)

0.014
0.020
0.000
0.013
0.009
0.013

StD

0.011

The absolute StD <0.1 means a good balance between two groups.

increased risk of headache was found in the nifedipine/felodipine þ SMS group with the use of
increased cumulative dosages of SMS (1e60 g SMS,
HR: 1.39; 95% CI: 1.11e1.74; >60 g SMS, HR: 1.97;
95% CI: 1.62e2.39; p-value for trend <0.0001). The
survival beneﬁt was also signiﬁcant with the cumulative use of SMS; the HR was 0.67 (95% CI:
0.47e0.94) for patients who used nifedipine/felodipine concurrently with SMS at an cumulative dose
of 1e60 g and 0.54 (95% CI: 0.37e0.79) for patients
who used nifedipine/felodipine concurrently with
SMS at an cumulative dose of >60 g ( p-value for

trend ¼ 0.001). The trends in the association of cumulative SMS doses with both headache and survival were statistically signiﬁcant.

4. Discussion
The changes in the pharmacokinetics of a victim
drug by a time-dependent CYP3A4 inhibitor
(perpetrator) can be affected by several factors of the
perpetrator, including the dosage, administration
time period, and tissue susceptibility to the inhibition [13,36]. Hepatic CYP3A has the main

Table 5. Effects of cumulative doses of SMS on health outcomes in patients taking nifedipine/felodipine.
Health outcomes

Headache
Low blood pressure
Acute myocardial infraction
Hospitalization of heart failure
All-cause mortality
Bone fracture

Hazard ratio (95% CI)
Nifedipine/Felodipine
(n ¼ 4,078)

Nifedipine/Felodipine þ SMS
(1e60 g) (n ¼ 428)

Nifedipine/Felodipine þ SMS
(>60 g) (n ¼ 388)

1.00
1.00
1.00
1.00
1.00
1.00

1.39
1.10
1.65
1.21
0.67
0.50

1.97
1.38
1.03
0.79
0.54
0.50

(1.11e1.74)
(0.48e2.54)
(0.90e3.04)
(0.85e1.73)
(0.47e0.94)
(0.12e2.07)

(1.62e2.39)
(0.66e2.90)
(0.50e2.14)
(0.52e1.20)
(0.37e0.79)
(0.12e2.07)

p value
for trend
<0.0001
0.693
0.267
0.274
0.001
0.275

contribution to the systemic elimination of nifedipine [3,4] and intestinal CYP3A contributes mainly
in the ﬁrst-pass elimination [9,10]. Both grapefruit
and SMS contain inhibitors, which inhibit NFO activity in a time-dependent manner [13,23], and
decrease intestinal CYP3A function [3,13,24]. The
bioavailability of nifedipine has been found to be
elevated in humans due to the consumption of
grapefruit juice, whereas its half-life, which is
associated with systemic elimination, remained unchanged in healthy volunteers [14,37]. Our previous
rat study using a 1-h treatment with a single dose of
SMS revealed that the increased plasma nifedipine
concentration primarily occurred in the elimination
phase, resulting in a prolonged half-life and unchanged Cmax [23]. This may be attributed to factors
such as the absorption lag time of SMS ingredients
(e.g., tmax in SMS (8 g/kg)-treated rats: schisandrin
B: 1.6 h; schisantherin A: 2.3 h [38]; tmax in Schisandra Fructus extract (5 g/kg)-treated rats: schisandrin B: 4.1 h [39]) during acute treatment. The
prolonged half-life was consistent with the
decreased hepatic NFO activity by the acute SMS
treatment. Our present ﬁndings showed that the
elevation in the Cmax and AUC0-t of nifedipine,
together with the reduction in nifedipine clearance
by 3-week SMS treatment suggest that the suppression of ﬁrst-pass metabolism can be a primary
factor in the SMS (3-week)-nifedipine interaction.
However, the elimination half-life of nifedipine was
not signiﬁcantly affected in rats after 3 weeks of
SMS treatment, which is consistent with the unchanged half-life of nifedipine after ingestion of
grapefruit juice [14,37]. Like the unchanged hepatic
CYP3A function after grapefruit ingestion [3], hepatic CYP3A protein level and activity were not
affected by repeated SMS treatments [24].
Compared with the pharmacokinetic changes
caused by a single dose of SMS, the 3-week-SMStreated rats showed a greater increase in Cmax and
AUC0-t values. These ﬁndings reveal the dynamic
inﬂuence of SMS on the pharmacokinetics of
nifedipine after acute and repeated treatments.
Ketoconazole increased the Cmax, AUC, and halflife of both nifedipine and dehydronifedipine,
resulting from its potent inhibitory effects on NFO
and glucuronidation activities [23,26]. The 2-week
SJW treatment signiﬁcantly increased liver microsomal activity of nifedipine oxidation to form
dehydronifedipine without affecting hepatic glucuronidation activity. The SJW treatment prolonged
the tmax and increased the clearance of nifedipine.
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However, the Cmax, AUC, and clearance of dehydronifedipine were insigniﬁcantly affected by this
repeated SJW treatment. Compared with ketoconazole-mediated changes, the 3-week SMS-elicited
increases in Cmax and AUC0-t of nifedipine were
moderate. The decrease in nifedipine clearance by
SMS was less than that by ketoconazole. The 2- and
3-week SMS treatments did not affect the elimination of dehydronifedipine, consistently with the
unchanged hepatic and intestinal glucuronidation
activities by SMS treatment [24]. Although that
functional inhibition of P-glycoprotein has been
suggested to partially contribute to the increased
bioavailability of nifedipine by pioglitazone in rats
[40], there was no evidence showing that transporters can be a limiting factor for the bioavailability
of nifedipine. More studies should be done to reveal
the contribution of inﬂux and efﬂux transporters in
the absorption and elimination of nifedipine.
The intestinal CYP3A was more susceptible to
SMS-mediated enzyme inhibition in rats after 3
weeks of SMS treatment than hepatic CYP3A [24]. In
consistent with that decreased intestinal NFO activity [24], nifedipine clearance signiﬁcantly decreased
after 3-week, but not 2-week, SMS treatment. The
decreased intestinal oxidation of nifedipine
decreased the ﬁrst-pass effect and increased plasma
concentration. Factors involved in the time-dependent decrease of intestinal NFO activity can comprise
the inhibitory behaviors of SMS ingredients, the
time-required accumulation of inactivated CYP3A,
and the imbalanced degradation/de novo synthesis
of CYP3A. The tmax of CYP3A inhibitors (>1.6 h) in
SMS were longer than that in grapefruit juice, bergamottin, (0.5 h) in rats [41], suggesting that,
compared to the events caused by grapefruit-juice
[3,14], the delayed absorption of SMS ingredients
prolonged the lag time required for CYP3A inactivation. In addition, the half-life of schisandrin B and
schisantherin A were 7 and 30 h in rats treated with
8 g/kg lyophilized SMS, respectively [38]. The halflife of methylophiopogonanone A was 8e9 h in rats
treated with Qingzao Jiufei decoction (4.6 g/kg) [42].
In our study, SMS were administered to rats once
daily. Thus, the time required for accumulating
schisantherin A to reach the steady-state was estimated to be at least 8 days. The increase in the AUC
of plasma felodipine after ﬁve-day grapefruit juice
ingestion was greater than that by a single glass of
juice [3], indicating that the accumulation of inactivated CYP3A is required for a greater increase of
AUC. The time-period for the signiﬁcantly detected
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suppression of CYP function by a time-dependent
inhibitor can be longer than that for the plasma level
of the inhibitor to reach the steady state [43]. Thus,
the time-period required for a signiﬁcant decrease of
CYP3A activity through the accumulation of inactivated CYP3A could be longer than 8 days. On the
other hand, our results showed the differential
CYP3A modulatory effects of multiple ingredients of
SMS component herbs. The interactions between
ingredients should also be considered in the drug
interaction assessment. Our ﬁndings revealed that a
3-week treatment was required for a signiﬁcant increase of nifedipine AUC0-t. The nearly 2-fold increase in systemic exposure to nifedipine after 3
weeks of SMS treatment in the rats alerted us to the
potential herb-drug interactions of SMS with nifedipine or other CYP3A4 drug substrates (oral and
ﬁrst-pass dependent) in patients.
The dosing regimen, complicated composition and
multiple modulator effects are determining factors
for the metabolic change-mediated drug interactions
caused by a compound decoction. For example, to
assess the pharmacokinetic interaction, rats were
treated with Shoseiryuto at a 10 times higher dose of
grapefruit juice due to that Shoseiryuto inhibited rat
CYP3A activity with an IC50 10-fold higher than
grapefruit juice [44]. The 30-min pre-treatment with
grapefruit juice, but not Shoseiryuto, signiﬁcantly
increased the Cmax of nifedipine. The differences in
the absorption, elimination and inhibition kinetics of
CYP3A inhibitors in grapefruit juice and Shoseiryuto
should be considered when the in vivo dose was
estimated from the IC50 values determined in vitro.
Accordingly, our previous ﬁndings revealed the
dose- [23] and time-dependent [24] decrease of
CYP3A function in SMS-treated rats. Microsomes
resuspended from pellets prepared by differential
centrifugation of intestinal mucosa from 3-week
SMS-treated rats had similar CYP3A protein levels
as the control group but impaired NFO function (a
38% decrease), supporting irreversible inactivation
through time-dependent inhibition in vivo. Among
the component herbs of SMS at their respective
doses corresponding to the amounts used for SMS
preparation, the decoction of Ophiopogonis Radix
irreversibly inactivated intestinal NFO activity. Our
current ﬁndings further demonstrate that, after
10 min of pre-incubation, schisandrin B, schisantherin A, and methylophiopogonanone A inhibit
NFO activity in rat hepatic and intestinal microsomes, as well as human CYP3A4 in vitro. The inﬂuence of Schisandra Fructus and its lignans on the

elimination of CYP3A substrates involves reversible
inhibition, time-dependent inhibition, and induction,
which could depend on the exposure dose and time
of treatment [45,46]. Our previous rat study showed
that Schisandra Fructus at its SMS-equivalent dose
did not impair hepatic and intestinal microsomal
NFO activity after 3 weeks of treatment [24]. However, reversible and partially irreversible inhibitors
can be removed during microsomal preparation.
Our present ﬁndings suggest that we cannot exclude
the involvement of the potent inhibitory effects of
schisandrin B and schisantherin A on CYP3A activity
over repeated treatments. In addition, the 3-day
treatment with 8 and 16 mg/kg/day schisandrin B
has been reported to increase the AUC of midazolam
in rats [47]. In rats orally treated with a single dose of
8 g/kg lyophilized SMS, the Cmax levels of plasma
schisantherin A and schisandrin B were 7.1 and
28.6 nM, respectively [38]. For causing a 2-fold increase in AUC, the predicted threshold of unbound
concentrations of schisantherin A and schisandrin B
were 0.34 and 7.69 nM in humans, respectively. According to the low threshold levels of these Schisandra lignans, their contribution to the SMSmediated pharmacokinetic interaction with CYP3A
drug substrates should be considered for further
human studies. Compared to Schisandra lignans, the
predicted threshold of methylophiopogonanone A
was higher. The CYP3A4 inactivation by methylophiopogonanone A could not be restored by dialysis, indicating the irreversible inhibition. The oral
effect of methylophiopogonanone A needs further
studies to show its contribution to the decreased
CYP3A function in Ophiopogonis Radix- and SMStreated rats [24]. Thus, in vivo, in addition to
impaired intestinal NFO activity via time-dependent
inactivation [24], the reversible or partially irreversible inhibition of hepatic and intestinal NFO by SMS
herbal ingredients or their metabolites could
contribute to the decreased clearance of nifedipine in
3-week SMS-treated rats, and possibly in humans.
Headache is the most common side effect of
nifedipine/felodipine with high plasma drug concentrations [1]. Consistent with the increased AUC
of plasma nifedipine after 3-week SMS treatment in
rats, the results of our retrospective study revealed
that patients with combined therapy with nifedipine/felodipine and SMS (>7 days) had higher
incidence of headaches, without elevating the risks
of more severe undesired effects, such as hypotension. SMS treatment was reported to cause headaches in one participant in a study of 15 healthy

volunteers [18]. However, there were no headache
and bone fracture in the adverse effects in a study,
which reviewed 14 randomized controlled trials (858
patients) of the outcome/adverse effects of SMS [48].
Although the baseline characteristics of the patients
were well-balanced between the groups in our
study, confounding factors, such as the CYP3A4
genotypes, dosage of nifedipine, formulation of
nifedipine/felodipine (e.g., immediate-release capsules and extended-release tablets) and disease
development, should be considered.
The results of our studies showed that there were no
signiﬁcant differences in composite cardiovascular
outcomes, including hospitalization for AMI and HHF
in the nifedipine/felodipine group with and without
SMS treatment. However, when patients received
both nifedipine/felodipine and SMS treatments, allcause mortality signiﬁcantly decreased. This
decreased mortality showed a signiﬁcant association
with increased accumulation of SMS dose. Among the
patients included in this study, 19e20% of them had
ischemic heart disease, 6e7% had congestive heart
failure, and 7% had suffered a stroke in both the
nifedipine/felodipine and nifedipine/felodipine þ
SMS treatment groups. The pharmacological activities of SMS are supported by published evidence,
such as the amelioration of inﬂammation in patients
who received percutaneous coronary intervention
[19] and myocardial protection against ischemic
injury in mice [49], suggesting that the therapeutic
efﬁcacy of SMS reduces mortality. The reduced mortality by SMS intervention highlights the beneﬁts of
herb-drug co-treatment and warrants future clinical
trials on patient health outcomes.
In conclusion, the laboratory rat study demonstrated that 3-week daily treatment with SMS
decreased the clearance of nifedipine and increased
systemic exposure. Rat NFO inhibitors in SMS herbs
also inhibited the NFO activity of human CYP3A4. A
retrospective population-based study revealed a potential beneﬁt on patient survival and increased risk
of headache with the combined use of nifedipine/
felodipine and SMS in patients with hypertension.

support the robustness of our ﬁndings. We obtained
excellent balance in baseline covariates across
treatment groups and consistent results using
several analytical approaches. Finally, the lack of an
observed effect on the negative control outcome of
bone fracture due to a vehicle accident suggests that
confounding is less likely to be a major concern.
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Supplementary Materials.
Supplementary Methods
Threshold concentration prediction
According to the high-throughput screening
method1 (Eq. 1) and inactivation kinetic method2,3
(Eq. 2), the threshold concentration required to
produce a doubling of the AUC was estimated. The
kdeg
values
for
CYP3A4
ranged
from
0.000146e0.0008252-4. The fm value of nifedipine and
kdeg value of CYP3A4 used for the threshold prediction were 0.9 and 0.0003, respectively2.
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5. Limitations
The current study has several limitations. First,
the population-based claims data analysis that was
used does not contain information related to risk
factors for death, such as smoking, family history,
and obesity. Second, although we employed many
methods to prevent possible confounders, potential
unmeasurable bias remains due to the observational
nature of our study design. However, several factors
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fm: fraction of nifedipine metabolized by CYP3A4
IC50(þ): the concentration causing 50% inhibition
of activity with NADPH-fortiﬁed pre-incubation
for a time-period of t
IC50(-): the concentration causing 50% inhibition
of activity without pre-incubation
[I]: unbound concentration of the inhibitor
kdeg: the rate constant of CYP3A4 degradation
kinact: the maximal inactivation rate constant
KI: the inhibitor concentration required for halfmaximal inactivation
t: pre-incubation time in the assay
Dialysis experiment
Membranes from bacteria expressing human
CYP3A4 and CPR (20 nM) were incubated with 3e20
mM methylophiopogonanone A in a ﬁnal volume of
400 mL (50 mM potassium phosphate buffer (pH 7.4),
10 mM glucose 6-phosphate, 0.5 mM NADPþ (sodium salt), glucose 6-phosphate dehydrogenase,
12.5 mM MgCl2) at 37  C for 30 min. Incubations
containing the same volume of dimethyl sulfoxide,
but no methylophiopogonanone A were used as
vehicle controls. After pre-incubation, the mixture
was placed on ice. A 200 mL aliquot was dialyzed
using a mini-dialysis unit (10 kDa cutoff, Thermo
Scientiﬁc-Pierce Biotechnology, Rockford, IL, USA)
against 120 mL of dialysis buffer (50 mM potassium
phosphate containing 0.1 mM EDTA at 4  C) with
three buffer changes at 30-min intervals. Aliquots of
10 mL and 75 mL were used for the determination of
NADPH-P450 reductase (CPR)4 and NFO activities.
In the determination of NFO activity, the aliquot
was added into a reaction mixture containing 29
mM potassium phosphate buffer (pH 7.85), 10 mM
glucose 6-phosphate, 0.5 mM NADPþ (sodium salt),
0.5 unit/mL glucose 6-phosphate dehydrogenase,
12.5 mM MgCl2 and 200 mM nifedipine. Oxidation
was carried out for 15 min, and the generation of
dehydronifedipine was determined as described in
the Methods section of the manuscript.
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Supplementary Results
Baseline Characteristics of Patients
A total of 34,324 patients with hypertension who
used nifedipine or felodipine between 2015 and 2017
were identiﬁed. After excluding those who used
other TCMs (n¼12,851) or had <7 cumulative drug
days of SMS usage during the follow-up period (for
the nifedipine/felodipineþSMS group) (n¼216),
21,473 eligible patients (nifedipine/felodipine: 20,441
patients; nifedipine/felodipineþSMS group: 1,032
patients) were included (Suppl. Fig. 1). After 1:5
PSM, 4,078 patients in the nifedipine/felodipine
group and 816 patients in the nifedipine/felodipineþSMS group were analyzed.
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Supplementary Fig. 1. Flowchart of patient selection. NF: nifedipine; FL: felodipine; SMS: Shengmai-San.

Table S2. Number of events, incident rates, and hazard ratios (HRs) of health outcomes.
NF/FL þ SMS co-treatment

NF/FL alone

Headache
LBP
AMI
HHF
All cause death
Bone fracture

No. of
event

Follow-up
duration
(person-year)

Incident Rate
(per 1,000
person-year)

No. of
event

Follow-up
duration
(person-year)

Incident Rate
(per 1,000
person-year)

638
56
75
292
486
39

11,173.72
12,234.00
12,234.00
11,907.76
12,315.56
12,274.78

57.10
4.58
6.13
24.52
39.46
3.18

205
14
20
58
61
3

2,211.36
2,537.76
2,537.76
2,472.48
2,570.40
2,562.24

92.70
5.52
7.88
23.46
23.73
1.17

HR
(95% CI)

P value

1.68
1.24
1.33
0.99
0.60
0.38

< 0.0001
0.4678
0.2533
0.9446
0.0002
0.1096

(1.44-1.97)
(0.69-2.23)
(0.81-2.18)
(0.75-1.31)
(0.46-0.78)
(0.12-1.24)

Abbreviations: LBP, low blood pressure; AMI, acute myocardial infraction; HHF: hospitalization due to heart failure.
There were 4,078 and 816 patients included in the data analyses of groups taking nifedipine/felodipine without (NF/FL alone) and with
the co-treatment with Shengmai-San (NF/FL þ SMS co-treatment), respectively. Low blood pressure: systolic blood pressure < 90 mmHg or diastolic blood pressure <60 mm-Hg.
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